ClinicalTrials.gg
CompletedNCT00243412RUMBAUpdated Oct 7, 2011Results posted

A Study of the Safety and Efficacy of Rituximab in Patients With Moderate to Severe Rheumatoid Arthritis Receiving Methotrexate

A Phase 2 interventional study of folate and methotrexate in Rheumatoid Arthritis, sponsored by Genentech, Inc.. Completed. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2011-10-07.

Sponsored by Genentech, Inc. (part of Hoffmann-La Roche) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
42
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 113 studies testing methotrexate in Arthritis, Rheumatoid — 8 open to participants now, 10 under way, 2 of them phase 3. Methotrexate · Arthritis, Rheumatoid.

Enrollment
89th of 113
42 · median 130
Started
2005
with 5 others
Phase 2
10 of 113
2 open now
Registered
9th of 113
by date
Lead sponsor
4 of 113
Genentech, Inc.

Among the 113 studies testing methotrexate in Arthritis, Rheumatoid, this one is the 89th largest by enrollment, is one of 6 that started in 2005, is one of 10 in phase 2, and was the 9th registered.

Arthritis, Rheumatoid

3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 445 are open to participants now.

Browse Arthritis, Rheumatoid studies →

Open to participants now

8 of the 113 studies testing methotrexate in Arthritis, Rheumatoid are open now, in 5 countries. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 8 open studies →

About methotrexate

Methotrexate: first FDA approval 1953 (METHOTREXATE SODIUM), first EMA approval 2016. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 293 Arthritis, Rheumatoid studies recruiting now, 150 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 113 studies testing methotrexate in Arthritis, Rheumatoid, or all of them as a file.
02

Study summary

This was a Phase II, randomized, double-blind, multicenter study designed to evaluate the safety and efficacy of rituximab, administered at two different regimens for 2 years, in patients with moderate to severe active rheumatoid arthritis (RA) receiving stable doses of methotrexate (MTX).

03

Conditions studied

  • Rheumatoid Arthritis

Keywords

  • Rituxan
  • RA
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of RA for at least 6 months.
  • Inadequate response to MTX
  • Use of folate
  • If female and of , have a negative serum pregnancy test within 8 weeks prior to first rituximab infusion

Exclusion criteria

Exclusion Criteria:

  • Diagnosis of juvenile idiopathic arthritis (also known as juvenile rheumatoid arthritis) and/or RA before age 16
  • Any surgical procedure, including bone/joint surgery or planned surgery within 8 weeks prior to screening or within 16 weeks of Week 1 (Day 1) visit
  • Inflammatory arthritis other than RA (e.g., inflammatory bowel disease, systemic lupus erythematosus (SLE), or psoriatic arthritis)
  • Functional Class IV as defined by the American College of Rheumatology (ACR) classification of functional status in RA
  • Use of disease-modifying anti-rheumatic drugs (DMARDs) other than MTX within 4 weeks prior to randomization (8 weeks prior for infliximab, adalimumab, or leflunomide)
  • Treatment with any agent within 4 weeks of screening or 5 half-lives of the investigational drug (whichever is longer)
  • Previous treatment with Tysabri\<TM> (natalizumab)
  • Previous treatment with rituximab
  • Previous treatment with any cell-depleting therapies, including investigational agents
  • Treatment with IV \&-globulin or Prosorba(R) Column within the previous 6 months
  • Use of intra-articular or parenteral within 4 weeks prior to screening visit
  • Receipt of a vaccine within 4 weeks prior to Day 1 infusion
  • History of severe allergic or anaphylactic reactions to humanized or murine monoclonal antibodies
  • Primary or secondary immunodeficiency (history of or active)
  • Evidence of significant uncontrolled concomitant diseases such as cardiovascular disease, nervous system, renal, hepatic, endocrine, gastrointestinal, or pulmonary disease, including any pulmonary or other condition that would preclude subject participation over the ensuing 2 years
  • Known active bacterial, viral, fungal, mycobacterial, or other infection (including tuberculosis or atypical mycobacterial disease, but excluding fungal infections of nail beds)
  • History of recurrent significant infection or any significant episode of infection requiring hospitalization or treatment with IV antibiotics within 4 weeks of screening or oral antibiotics within 2 weeks prior to screening
  • History of significant cytopenias or other bone marrow disorders
  • History of cancer, including solid tumors and hematologic (except basal cell and squamous cell carcinoma of the skin that have been excised and cured)
  • Pregnant or nursing (breast feeding) women
  • Lack of peripheral venous access
  • Chronic daily use of narcotic analgesics
  • History of alcohol, drug, or chemical abuse within 6 months prior to screening
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
42 participants (actual)

Study arms

  • Experimental
    Arm A: 500 mg Rituximab

    Rituximab: 1000 mg intravenous (IV) on Days 1 and 15 of the first cycle; 500 mg IV on Days 1 and 15 of each subsequent 6-month cycle (Months 6, 12, and 18). Corticosteroids: 100 mg IV methylprednisolone prior to each rituximab infusion. Methotrexate: 15-25 mg/wk oral or parenteral (10-14 mg/wk if intolerant). Folate: Minimum of 1 mg/day (or folinic acid 5 mg/wk).

    Drug: folate · Drug: methotrexate · Drug: methylprednisolone · Drug: Rituximab

  • Experimental
    Arm B: 1000 mg Rituximab

    Rituximab: 1000 mg IV on Days 1 and 15 of each 12-month cycle (Rituximab cycles were administered at baseline and Month 12.) For the Month 6 and 18 cycles, rituximab or placebo was administered. Corticosteroids: 100 mg IV methylprednisolone prior to each rituximab infusion For the Months 6 and 18 cycles, IV saline was administered prior to each rituximab or placebo infusion. Methotrexate: 15-25 mg/wk oral or parenteral (10-14 mg/wk if intolerant). Folate: Minimum of 1 mg/day (or folinic acid 5 mg/wk).

    Drug: folate · Drug: methotrexate · Drug: methylprednisolone · Drug: Placebo · Drug: Rituximab

Interventions

  • Drugfolate

    Minimum of 1 mg/day oral (or folinic acid 5 mg/week)

  • 15-25 mg/week oral or parenteral (10-14 mg/week if intolerant)

  • 100 mg intravenous (IV) prior to each rituximab infusion (For Arm B, for the Months 6 and 18 cycles, IV saline was administered prior to each placebo infusion)

  • DrugPlacebo

    To maintain the blind, patients in Arm B (Rituximab 1000 mg) received placebo infusions at Months 6 and 18.

  • 500 mg or 1000 mg IV\*2.

06

What researchers measure

Primary outcomes

  1. Number of Participants With Either an Infection or a Grade III or IV Adverse Event (National Cancer Institute Common Toxicity Criteria for Adverse Events [NCI CTCAE], Version 3.0)

    A Grade III Adverse Event (AE) is severe; defined as considerable interference with the subject's daily activities, medical intervention/therapy required and hospitalization possible. A Grade IV AE is life-threatening; defined as extreme limitation in activity, significant medical intervention/therapy required, hospitalization probable. Because of the small sample size and the small number of subjects who completed Week 104, the analysis were limited to descriptive statistics only.

    Time frame: 24 months

Secondary outcomes

  1. Change From Baseline in Disease Activity Score 28-4 C-reactive Protein (DAS28-4(CRP))

    The DAS28-4(CRP) score is a measure of the subject's disease activity. DAS28-4(CRP) is based on the tender joint count (28 joints), swollen joint count (28 joints), patient's global assessment of disease activity and CRP. DAS28 provides a number on a scale (0 to 10) indicating current disease activity. A score above 5.1 means high disease activity and a score below 3.2 indicates low disease activity. Change from baseline at 24 months was analyzed for DAS28-4 (CRP).

    Time frame: Baseline, 24 months

  2. Number of Participants With American College of Rheumatology Responses (ACR20, ACR50, and ACR70)

    ACR20 response was defined as satisfying the following 3 criteria improvement from baseline: ≥ 20% in tender joint count; ≥ 20% in swollen joint count; ≥ 20% improvement from baseline in 3 of the following 5 criteria: Subject's Global Assessment of Pain Subject's Global Assessment of Disease Activity Physician's Global Assessment Subject's Self-Assessment Erythrocyte sedimentation rate (ESR) or C-reactive protein (CRP) Note: The definitions of ACR50 and ACR70 are the same as ACR20, except that the 20% value in the above definition is replaced by 50% and 70% values, respectively.

    Time frame: Baseline, 24 months

  3. Number of Participants With American College of Rheumatology (ACR) Major Clinical Response and/or Remission

    Major clinical response is an ACR70 response defined as improvement from baseline: ≥70% in tender joint count; ≥70% in swollen joint count; ≥70% in 3 of the following: Patient Pain Assessment, Patient Global Assessment, Physician Global Assessment, Patient Self-Assessed Disability, ESR or CRP for ≥169 consecutive days. Remission: ≥5 requirements fulfilled for ≥2 consecutive months: Duration of morning stiffness \<15 minutes, No fatigue, No joint pain, No joint tenderness or pain on motion, No soft tissue swelling in joints or tendon sheaths, ESR \<30 mm/hour for women and \<20 mm/hour for men.

    Time frame: 24 months

  4. Number of Participants With European League Against Rheumatism (EULAR) Response and Remission Using Disease Activity Score 28-4 (DAS28-4)C-reactive Protein (CRP)

    EULAR remission = DAS28-4(CRP) \< 2.6 (Fransen et al. 2004. EULAR response categories (van Gestel et al. 1999): Good response = final DAS28-4(CRP) \< 3.2 and decreased \> 1.2 points from baseline Moderate response = final DAS28-4(CRP) ≥ 3.2 but ≤ 5.1 and decreased \> 0.6 points from baseline or final DAS28-4(CRP) \> 5.1 and decreased \> 1.2 from baseline.

    Time frame: Baseline, 24 months

  5. Change From Baseline in Short Form 36 (SF 36) Summary and Subscale Scores

    The SF-36 is a questionnaire used to assess physical functioning and is made up of eight domains: Physical Functioning (PF), Role Physical (RP), Bodily Pain(BP), General Health (GH), Vitality (VT), Social Functioning (SF), Role-Emotional (RE),Mental Health (MH). Transforming and standardizing these domains leads to the calculation of the Physical (PCS) and Mental (MCS) Component Summary measures. Scores ranging from 0 to 100, with 0=worst score (or quality of life) and 100=best score.

    Time frame: Baseline, 24 Months

  6. Change From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI)

    The Stanford HAQ-DI is a patient-reported questionnaire specific for RA. It consists of 20 questions referring to eight component sets: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and activities. The questionnaire was provided in a certified translation of the local languages at the participating sites and was scored based on the instructions from the Stanford University Medical Center.The questions are evaluated on a 4-point scale: 0=without any difficulty, 1= with some difficulty, 2= with much difficulty, and 3= unable to do. Higher scores= greater dysfunction.

    Time frame: Baseline, 24 Months

  7. Change From Baseline in Functional Assessment for Chronic Illness Therapy-Fatigue (FACIT-F)

    FACIT-F is a 13-item questionnaire. Patients scored each item on a 5-point scale: 0 (Not at all) to 4 (Very much). The larger the patient's response to the questions (with the exception of 2 negatively stated), the greater the patient's fatigue. For all questions, except for the 2 negatively stated ones, the code was reversed and a new score was calculated as (4 minus the patient's response). The sum of all responses resulted in the FACIT-Fatigue score for a total possible score of 0 (worse score) to 52 (better score). A higher score reflects an improvement in the patient's health status.

    Time frame: Baseline, 24 Months

  8. DAS28-4 Erythrocyte Sedimentation Rate(ESR)

    The DAS28-4(ESR) score is a measure of the subject's disease activity. It is based on the tender joint count (28 joints), swollen joint count (28 joints), patient's global assessment of disease activity (mm), and ESR. DAS28-4(ESR) scores range from 0 - 10, where a score of less than or equal to 3.2 implies well controlled disease and greater than or equal to 5.1 implies active disease In this trial, CRP rather than ESR was used, unless the CRP value was missing at both Day 1 and screening, in which case ESR value was used.

    Time frame: 24 Months

  9. Change From Baseline in Rheumatoid Factor (RF)

    Serum levels of rheumatoid factor at baseline, month 24 and change from baseline to month 24.

    Time frame: Baseline, 24 Months

  10. Change From Baseline in Cyclic Citrullinated Peptide (CCP) Antibodies/Cytokines

    Because of the different laboratory methods that were used to measure anti-CCP antibody levels, no summary statistics were calculated.

    Time frame: Baseline, 24 Months

07

Results

Posted Oct 7, 2011
Limitations and caveats
Because of the limited sample size, interpretation of these results should be made with caution and therefore definitive conclusions cannot be made regarding differences between the two retreatment regimens studied.

Participant flow

Approximately 40 subjects with moderately to severely active rheumatoid arthritis were to be enrolled at six to eight study centers in the United States and were randomly assigned in a 1:1 ratio to Arm A or B. Starting 15 August 2005 to 4 February 2009 (first subject enrolled to database lock).

Participant flow — Overall Study
MilestoneArm A: 500 mg RituximabArm B: 1000 mg Rituximab
Started2121
Safety evaluable2120
Completed1110
Not completed1011
Withdrew: Death01
Withdrew: Adverse event42
Withdrew: Lost to follow-up01
Withdrew: Physician decision11
Withdrew: Withdrawal by subject45
Withdrew: Other11

Outcome measures

PrimaryNumber of Participants With Either an Infection or a Grade III or IV Adverse Event (National Cancer Institute Common Toxicity Criteria for Adverse Events [NCI CTCAE], Version 3.0)

A Grade III Adverse Event (AE) is severe; defined as considerable interference with the subject's daily activities, medical intervention/therapy required and hospitalization possible. A Grade IV AE is life-threatening; defined as extreme limitation in activity, significant medical intervention/therapy required, hospitalization probable. Because of the small sample size and the small number of subjects who completed Week 104, the analysis were limited to descriptive statistics only.

Time frame:
24 months
Reported as:
Number · Participants
Number of Participants With Either an Infection or a Grade III or IV Adverse Event (National Cancer Institute Common Toxicity Criteria for Adverse Events [NCI CTCAE], Version 3.0)
ParticipantsArm A: 500 mg RituximabArm B: 1000 mg Rituximab
Infections1411
Adverse Events (Grade 3 or 4)54
SecondaryChange From Baseline in Disease Activity Score 28-4 C-reactive Protein (DAS28-4(CRP))

The DAS28-4(CRP) score is a measure of the subject's disease activity. DAS28-4(CRP) is based on the tender joint count (28 joints), swollen joint count (28 joints), patient's global assessment of disease activity and CRP. DAS28 provides a number on a scale (0 to 10) indicating current disease activity. A score above 5.1 means high disease activity and a score below 3.2 indicates low disease activity. Change from baseline at 24 months was analyzed for DAS28-4 (CRP).

Time frame:
Baseline, 24 months
Reported as:
Mean · Scores on a scale
Change From Baseline in Disease Activity Score 28-4 C-reactive Protein (DAS28-4(CRP))
Scores on a scaleArm A: 500 mg RituximabArm B: 1000 mg Rituximab
Baseline6.53 ± 0.706.33 ± 0.85
Month 244.03 ± 1.753.77 ± 1.42
Change from baseline-2.49 ± 1.85-2.56 ± 1.23
SecondaryNumber of Participants With American College of Rheumatology Responses (ACR20, ACR50, and ACR70)

ACR20 response was defined as satisfying the following 3 criteria improvement from baseline: ≥ 20% in tender joint count; ≥ 20% in swollen joint count; ≥ 20% improvement from baseline in 3 of the following 5 criteria: Subject's Global Assessment of Pain Subject's Global Assessment of Disease Activity Physician's Global Assessment Subject's Self-Assessment Erythrocyte sedimentation rate (ESR) or C-reactive protein (CRP) Note: The definitions of ACR50 and ACR70 are the same as ACR20, except that the 20% value in the above definition is replaced by 50% and 70% values, respectively.

Time frame:
Baseline, 24 months
Reported as:
Number · Participants
Number of Participants With American College of Rheumatology Responses (ACR20, ACR50, and ACR70)
ParticipantsArm A: 500 mg RituximabArm B: 1000 mg Rituximab
ACR20 Responders76
ACR50 Responders45
ACR70 Responders43
SecondaryNumber of Participants With American College of Rheumatology (ACR) Major Clinical Response and/or Remission

Major clinical response is an ACR70 response defined as improvement from baseline: ≥70% in tender joint count; ≥70% in swollen joint count; ≥70% in 3 of the following: Patient Pain Assessment, Patient Global Assessment, Physician Global Assessment, Patient Self-Assessed Disability, ESR or CRP for ≥169 consecutive days. Remission: ≥5 requirements fulfilled for ≥2 consecutive months: Duration of morning stiffness \<15 minutes, No fatigue, No joint pain, No joint tenderness or pain on motion, No soft tissue swelling in joints or tendon sheaths, ESR \<30 mm/hour for women and \<20 mm/hour for men.

Time frame:
24 months
Reported as:
Number · Participants
Number of Participants With American College of Rheumatology (ACR) Major Clinical Response and/or Remission
ParticipantsArm A: 500 mg RituximabArm B: 1000 mg Rituximab
Number of Participants With American College of Rheumatology (ACR) Major Clinical Response and/or Remission10
SecondaryNumber of Participants With European League Against Rheumatism (EULAR) Response and Remission Using Disease Activity Score 28-4 (DAS28-4)C-reactive Protein (CRP)

EULAR remission = DAS28-4(CRP) \< 2.6 (Fransen et al. 2004. EULAR response categories (van Gestel et al. 1999): Good response = final DAS28-4(CRP) \< 3.2 and decreased \> 1.2 points from baseline Moderate response = final DAS28-4(CRP) ≥ 3.2 but ≤ 5.1 and decreased \> 0.6 points from baseline or final DAS28-4(CRP) \> 5.1 and decreased \> 1.2 from baseline.

Time frame:
Baseline, 24 months
Reported as:
Number · Participants
Number of Participants With European League Against Rheumatism (EULAR) Response and Remission Using Disease Activity Score 28-4 (DAS28-4)C-reactive Protein (CRP)
ParticipantsArm A: 500 mg RituximabArm B: 1000 mg Rituximab
No Response00
Moderate Response26
Good Response54
Eular Remission33
SecondaryChange From Baseline in Short Form 36 (SF 36) Summary and Subscale Scores

The SF-36 is a questionnaire used to assess physical functioning and is made up of eight domains: Physical Functioning (PF), Role Physical (RP), Bodily Pain(BP), General Health (GH), Vitality (VT), Social Functioning (SF), Role-Emotional (RE),Mental Health (MH). Transforming and standardizing these domains leads to the calculation of the Physical (PCS) and Mental (MCS) Component Summary measures. Scores ranging from 0 to 100, with 0=worst score (or quality of life) and 100=best score.

Time frame:
Baseline, 24 Months
Reported as:
Mean · Units on a Scale
Change From Baseline in Short Form 36 (SF 36) Summary and Subscale Scores
Units on a ScaleArm A: 500 mg RituximabArm B: 1000 mg Rituximab
Summary Score: Mental Component Score7.69 ± 16.102.28 ± 10.42
Summary Score: Physical Component Score9.88 ± 12.314.93 ± 9.83
Subscale: Bodily Pain26.64 ± 26.648.00 ± 22.55
Subscale: General Health13.86 ± 18.7818.40 ± 23.55
Subscale: Mental Health20.00 ± 18.172.50 ± 26.48
Subscale: Physical Function21.62 ± 35.4515.72 ± 17.54
Subscale: Role Emotional16.67 ± 45.958.33 ± 24.85
Subscale: Role Physical34.09 ± 31.17-1.25 ± 23.90
Subscale: Social Functioning21.59 ± 35.837.50 ± 25.14
Subscale: Vitality10.61 ± 26.038.13 ± 12.86
SecondaryChange From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI)

The Stanford HAQ-DI is a patient-reported questionnaire specific for RA. It consists of 20 questions referring to eight component sets: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and activities. The questionnaire was provided in a certified translation of the local languages at the participating sites and was scored based on the instructions from the Stanford University Medical Center.The questions are evaluated on a 4-point scale: 0=without any difficulty, 1= with some difficulty, 2= with much difficulty, and 3= unable to do. Higher scores= greater dysfunction.

Time frame:
Baseline, 24 Months
Reported as:
Mean · Scores on a scale
Change From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI)
Scores on a scaleArm A: 500 mg RituximabArm B: 1000 mg Rituximab
Change From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI)-0.60 ± 0.87-0.45 ± 0.72
SecondaryChange From Baseline in Functional Assessment for Chronic Illness Therapy-Fatigue (FACIT-F)

FACIT-F is a 13-item questionnaire. Patients scored each item on a 5-point scale: 0 (Not at all) to 4 (Very much). The larger the patient's response to the questions (with the exception of 2 negatively stated), the greater the patient's fatigue. For all questions, except for the 2 negatively stated ones, the code was reversed and a new score was calculated as (4 minus the patient's response). The sum of all responses resulted in the FACIT-Fatigue score for a total possible score of 0 (worse score) to 52 (better score). A higher score reflects an improvement in the patient's health status.

Time frame:
Baseline, 24 Months
Reported as:
Mean · Scores on a scale
Change From Baseline in Functional Assessment for Chronic Illness Therapy-Fatigue (FACIT-F)
Scores on a scaleArm A: 500 mg RituximabArm B: 1000 mg Rituximab
Change From Baseline in Functional Assessment for Chronic Illness Therapy-Fatigue (FACIT-F)9.64 ± 15.548.80 ± 12.15
SecondaryDAS28-4 Erythrocyte Sedimentation Rate(ESR)

The DAS28-4(ESR) score is a measure of the subject's disease activity. It is based on the tender joint count (28 joints), swollen joint count (28 joints), patient's global assessment of disease activity (mm), and ESR. DAS28-4(ESR) scores range from 0 - 10, where a score of less than or equal to 3.2 implies well controlled disease and greater than or equal to 5.1 implies active disease In this trial, CRP rather than ESR was used, unless the CRP value was missing at both Day 1 and screening, in which case ESR value was used.

Time frame:
24 Months
Reported as:
Mean · Scores on a scale
DAS28-4 Erythrocyte Sedimentation Rate(ESR)
Scores on a scaleArm A: 500 mg RituximabArm B: 1000 mg Rituximab
DAS28-4 Erythrocyte Sedimentation Rate(ESR)4.25 ± 1.984.32 ± 1.39
SecondaryChange From Baseline in Rheumatoid Factor (RF)

Serum levels of rheumatoid factor at baseline, month 24 and change from baseline to month 24.

Time frame:
Baseline, 24 Months
Reported as:
Mean · IU/mL
Change From Baseline in Rheumatoid Factor (RF)
IU/mLArm A: 500 mg RituximabArm B: 1000 mg Rituximab
Baseline542.8 ± 1011.6243.7 ± 280.2
Month 2443.0 ± 70.841.4 ± 34.3
Change from Baseline to Month 24-499.8 ± 946.9-202.3 ± 279.1
SecondaryChange From Baseline in Cyclic Citrullinated Peptide (CCP) Antibodies/Cytokines

Because of the different laboratory methods that were used to measure anti-CCP antibody levels, no summary statistics were calculated.

Time frame:
Baseline, 24 Months
Reported as:
Number · units

No measurements were reported for this outcome.

Adverse events

Collected over Duration includes safety-evaluable subjects during the 2-year treatment period; in addition Serious adverse events that occurred during safety follow-up.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Arm A: 500 mg Rituximab—3/21 (14.3%)21/21 (100%)
Arm B: 1000 mg Rituximab—2/20 (10%)14/20 (70%)
Most frequent serious events
Most frequent serious events
EventArm A: 500 mg RituximabArm B: 1000 mg Rituximab
DEATHCardiac disorders0/211/20
MALIGNANT MELANOMANeoplasms benign, malignant and unspecified (incl cysts and polyps)0/211/20
NON-CARDIAC CHEST PAINGeneral disorders1/210/20
UTERINE LEIOMYOMANeoplasms benign, malignant and unspecified (incl cysts and polyps)1/210/20
INTRACRANIAL ANEURYSMNervous system disorders1/210/20
Most frequent other events
Showing 10 of 30
Most frequent other events
EventArm A: 500 mg RituximabArm B: 1000 mg Rituximab
Upper respiratory tract infectionInfections and infestations3/217/20
SinusitisInfections and infestations6/211/20
NauseaGastrointestinal disorders5/211/20
ArthralgiaMusculoskeletal and connective tissue disorders5/212/20
DiarrheaGastrointestinal disorders4/211/20
Pain in extremityMusculoskeletal and connective tissue disorders4/212/20
Back painMusculoskeletal and connective tissue disorders4/211/20
InsomniaNervous system disorders4/213/20
RashSkin and subcutaneous tissue disorders4/213/20
Urinary tract infectionInfections and infestations2/213/20

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Arm A: 500 mg RituximabArm B: 1000 mg RituximabTotal
<=18 years000
Between 18 and 65 years212041
>=65 years011
Age Continuous
Age Continuous(years)Arm A: 500 mg RituximabArm B: 1000 mg RituximabTotal
Mean46.9 ± 9.647.4 ± 11.147.2 ± 10.3
Sex: Female, Male
Sex: Female, Male(Participants)Arm A: 500 mg RituximabArm B: 1000 mg RituximabTotal
Female191837
Male235
08

Study locations

No study locations are listed for this record.

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 2005, a primary completion of Feb 2009 and a completion of Feb 2009. It does not say whether these dates are actual or estimated.

Results were first posted in Oct 2011, 2 years 8 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 21, 2005
First posted
Oct 24, 2005
Start
Aug 2005
Primary completionActual
Feb 2009
CompletionActual
Feb 2009
Results first posted
Oct 7, 2011
Last update
Oct 7, 2011
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 7, 2011, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00243412
Lead sponsor
Genentech, Inc.
Responsible party
Sponsor
First posted
Oct 24, 2005
Start date
Aug 2005
Primary completion
Feb 2009
Completion
Feb 2009
Results posted
Oct 7, 2011
Last update
Oct 7, 2011

Study contacts

William Reiss, Pharm.D.
study director · Genentech, Inc.
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Methotrexate · Rituximab

Start the discussion